Country: Malta
Language: English
Source: Medicines Authority
IBUPROFEN
Mepha LDA. Lagoas Park, Edificio 5A, Piso 2, 2740-298 Porto Salvo, Portugal
M01AE01
IBUPROFEN 200 mg
FILM-COATED TABLET
IBUPROFEN 200 mg
OTC
ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
Withdrawn
2006-11-02
PACKAGE LEAFLET: INFORMATION FOR THE USER IRFEN QUIKTABS ibuprofen READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Irfen is and what it is used for 2. What you need to know before you take Irfen 3. How to take Irfen 4. Possible side effects 5. How to store Irfen 6. Contents of the pack and other information 1. WHAT IRFEN IS AND WHAT IT IS USED FOR Irfen belongs to a group of medicines called NSAIDs (non-steroidal anti-inflammatory drugs) which work by reducing pain, inflammation and fever. Irfen is used to treat the following conditions in adults and children aged 12 years and older: provide relief from mild to moderate pain such as headache, toothache, period pain, post- traumatic pain (sprains, contusions, dislocations, fractures), post-surgical pain (general surgery, episiotomy, dental extraction) treat fever treatment of rheumatoid arthritis, osteoarthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, extra-articular rheumatism or other inflammatory or painful joint conditions, as well as for inflammatory and painful conditions of soft tissues. 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE IRFEN DO NOT TAKE IRFEN: - if you are allergic to ibuprofen or any of the other ingredients of this medicine - if you have had allergic reactions such as asthma, bronchospasm, runny nose, itchy skin rash or swelling of the lips, face, tongue, or throat after you have taken medicines containing acetylsalicylic acid (aspirin) or other drugs for pain and inflammation (NSAIDs) - if you have s Read the complete document
Page 1 of 6 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Irfen-200 Quiktabs 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each Quiktab contains 200 mg ibuprofen. For a full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Film-coated tablet 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Inflammatory and degenerative rheumatic diseases of the joints and soft tissue. Non-rheumatic pain such as primary dysmenorrhea, headache and toothache, postoperative pain. Fever. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Undesirable effects may be minimised by using the lowest effective dose for the shortest duration necessary to control symptoms (see section 4.4). _ _ _Usual dosage_ Irfen Quiktabs are taken without chewing during or after a meal with little fluid. For oral administration and short-term use only. During short-term use, if symptoms persist or worsen the patient should be advised to consult a doctor. Adults and children over 12 years: The minimum effective dose should be used for the shortest time necessary to relieve symptoms. If the product is required for more than 10 days, or if the symptoms worsen the patient should consult a doctor. Take 1 or 2 tablets with water, up to three times a day as required. Leave at least four hours between doses. Do not take more than 6 tablets in any 24 hour period. Not for use by children under 12 years of age. _Maximum dose: _ The respective dosing interval should be chosen in line with the observed symptoms and the Page 2 of 6 maximum recommended daily dose. It should not be below 6 hours dose. A total dose of 1200 mg ibuprofen should not be exceeded in any 24-hour period. _Elderly patients _ No special dose adjustment is required. Because of the possible undesirable-effect profile (see section 4.4), the elderly should be monitored particularly carefully. _ _ _Patients with renal impairment _ No dose reduction is required in patients with mild to moderate impairment to renal function (for patients with severe renal insufficiency, see section Read the complete document